Affinity’s technology platforms encompass TMEA‑ALDC, TMEA‑SMDC, TMEA‑ADC, TMEAboby, TMEAakine and TMEA‑TCE, enabling the engineering of diverse molecules including small‑molecule therapeutics, cytokines, antibodies and fusion proteins. The platforms feature robust scalability and broad application potential. Affinity independently develops multiple candidate molecules at different stages of research and development, with potential First‑in‑class or Best‑in‑class profiles. The Company actively pursues global collaboration and out‑licensing opportunities.

